Company news
Adial Pharmaceuticals, Inc (NASDAQ:ADIL) news
Adial Pharmaceuticals, Inc news releases on 6ix. Latest, Nov 29, 2021: Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate…
Press releases — page 3
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer
November 28, 2021
Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options
November 9, 2021
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments
November 8, 2021
Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors
November 2, 2021
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as Drug Candidate for the Treatment of Pain
October 20, 2021
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
September 29, 2021
Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
September 27, 2021
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
August 30, 2021
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
August 19, 2021
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
August 11, 2021
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
August 9, 2021
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
August 4, 2021
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
July 13, 2021
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
July 6, 2021
Adial Joins Russell Microcap® Index
June 27, 2021
Adial Pharmaceuticals Provides Regulatory and Development Update
June 23, 2021
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test
June 21, 2021
Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
June 2, 2021
Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
March 14, 2021
Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants
February 25, 2021
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
February 24, 2021
Adial to File Fast Track Application for AD04 with the FDA
February 22, 2021
Adial Pharmaceuticals Closes Acquisition of Purnovate
January 25, 2021
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
January 10, 2021
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder
December 16, 2020
Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory
December 14, 2020
Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments
December 9, 2020
Adial Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment of Addiction
December 9, 2020
Adial Pharmaceuticals Enters into Common Stock Purchase Agreement with Keystone Capital Partners to Support Strategic Opportunities and Future Growth Initiatives
November 24, 2020
Adial Pharmaceuticals Provides Update on its ONWARD(TM) Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder
November 2, 2020
Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder
October 20, 2020
Adial Pharmaceuticals Announces Sale of 10,000 COVID-19 Antibody Rapid Test Devices
September 29, 2020
Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples
September 28, 2020
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA
September 24, 2020
Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales
September 21, 2020
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits
August 5, 2020
Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call
July 27, 2020
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder
July 21, 2020
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia
July 5, 2020